{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444274830
| IUPAC_name = (2''S'',4''E'')-5-(5-isopropoxypyridin-3-yl)-''N''-methylpent-4-en-2-amine
| image = Ispronicline.png
| width = 240

<!--Clinical data-->
| tradename = 
| routes_of_administration =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 252870-53-4
| ATC_prefix = none
| ATC_suffix = 
| PubChem = 9824145
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 3E05NBH9V5
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08935
 | DrugBank          = 
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 7999892

<!--Chemical data-->
| C=14 | H=22 | N=2 | O=1 
| molecular_weight = 234.336
| smiles            = C[C@@H](C/C=C/C1=CC(=CN=C1)OC(C)C)NC
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C14H22N2O/c1-11(2)17-14-8-13(9-16-10-14)7-5-6-12(3)15-4/h5,7-12,15H,6H2,1-4H3/b7-5+/t12-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = RPCVIAXDAUMJJP-PZBABLGHSA-N
}}

'''Ispronicline''' ('''TC-1734''', '''AZD-3480''') is an experimental  drug which acts as a [[partial agonist]] at neural [[nicotinic acetylcholine receptor]]s. It progressed to phase II clinical trials  for the treatment of [[dementia]] and [[Alzheimer's disease]], but is no longer under [[drug development|development]].<ref name=failed>[http://cdn-templates.cxpublic.com/AdSpaceProduction_000000015fa57611.html# Targacept Drops Development of Alzheimer's Drug]</ref>

Ispronicline is subtype-selective, binding primarily to the [[Alpha-4 beta-2 nicotinic receptor|α4β2]] [[nicotinic acetylcholine receptor#Subunits|subtype]]. It has [[antidepressant]], [[nootropic]] and [[neuroprotective]] effects.{{medcn|date=July 2014}}

Early stage clinical trials showed that ispronicline was well tolerated, with the main side effects being [[dizziness]] and [[headache]].<ref>Gatto GJ, Bohme GA, Caldwell WS, Letchworth SR, Traina VM, Obinu MC, Laville M, Reibaud M, Pradier L, Dunbar G, Bencherif M. TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. ''CNS Drug Reviews''. 2004 Summer;10(2):147-66. {{PMID|15179444}}</ref><ref>Dunbar G, Demazières A, Monreal A, Cisterni C, Metzger D, Kuchibhatla R, Luthringer R. Pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers. ''Journal of Clinical Pharmacology''. 2006 Jul;46(7):715-26. {{PMID|16809797}}</ref><ref>Lippiello P, Letchworth SR, Gatto GJ, Traina VM, Bencherif M. Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties. ''Journal of Molecular Neuroscience''. 2006;30(1-2):19-20. {{PMID|17192610}}</ref><ref>Dunbar G, Boeijinga PH, Demazières A, Cisterni C, Kuchibhatla R, Wesnes K, Luthringer R. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. ''Psychopharmacology''. 2007 May;191(4):919-29. {{DOI|10.1007/s00213-006-0675-x}} {{PMID|17225162}}</ref><ref>Dunbar GC, Inglis F, Kuchibhatla R, Sharma T, Tomlinson M, Wamsley J. Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI). ''Journal of Psychopharmacology''. 2007 Mar;21(2):171-8. {{PMID|17329297}}</ref> However, mid stage clinical trials failed to show sufficient [[efficacy]] to continue development as a pharmaceutical drug.<ref name=failed/>

== References ==
{{Reflist|2}}

{{Stimulants}}
{{Nootropics}}
{{Antidementia}}
{{Antidepressants}}
{{Nicotinic acetylcholine receptor modulators}}

[[Category:Nootropics]]
[[Category:Pyridines]]
[[Category:Nicotinic agonists]]
[[Category:Stimulants]]
[[Category:Phenol ethers]]
[[Category:Amines]]


{{nervous-system-drug-stub}}